Novartis migraine drug not cost effective - UK price watchdog

Britain's drug price watchdog on Thursday rejected Novartis's migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news